LILLY DRN

These are 3 big things we’re watching in the stock market this week

Read more

Novo Nordisk’s diabetes pill Rybelsus slashes cardiovascular risk

Read more

Zepbound copycats remain online despite FDA ban

Read more

Jim Cramer’s 6 favorite stocks now, plus updates on rest of portfolio

Read more

FDA says Wegovy and Ozempic shortage resolved; Hims & Hers stock falls

Read more

Trump health care plan likely good for pharmaceutical companies

Read more

Medicare drug price negotiations list includes Ozempic

Read more

Eli Lilly LLY cuts 2024 revenue outlook on weight loss drugs

Read more

High-cost weight loss drugs boost nutrition counseling with employers

Read more

Medicare can cover Eli Lilly’s Zepbound for sleep apnea: Health Department

Read more